Dr. Kevin Christopher Brennan's lab focuses on understanding migraines, a debilitating condition that affects millions globally. The research investigates the mechanisms behind migraine attacks, particularly how sensory phenomena like auras may indicate the progression of migraines. By combining imaging techniques and physiological assessments, the lab aims to identify biomarkers that predict migraine severity and progression, ultimately helping to develop better treatments and preventative strategies.

Dr. Bruce L. Miller's research lab at UCSF focuses on understanding and addressing dementia in Latino populations, a group that has been historically underrepresented in dementia research. Through a multi-partner consortium, the lab investigates the effects of socioeconomic factors, genetic variants, and brain aging on Alzheimer's disease and frontotemporal lobar degeneration. By gathering data from participants across Latin America and the United States, the lab aims to develop culturally tailored interventions to improve dementia care and outcomes.

Dr. Michael I. Miller leads a research lab at Johns Hopkins University focused on understanding how Alzheimer's disease affects specific brain regions, particularly the entorhinal cortex, which deteriorates early in the disease. The lab employs advanced MRI techniques along with histological and molecular analyses to correlate structural brain changes with cognitive impairment and disease progression. This research aims to develop new MRI-based biomarkers that could aid in the early detection and treatment of Alzheimer's disease.

Dr. Chad Mirkin's lab focuses on using innovative nanotechnology to develop new vaccines for melanoma, a challenging form of skin cancer. They explore spherical nucleic acids (SNAs) that can deliver targeted immune responses to combat tumor cells. This research aims to improve treatment outcomes for melanoma patients and advance the field of cancer immunotherapy.

Dr. Sarah B. Berman's lab focuses on understanding how mitochondrial dysfunction affects energy metabolism in the brain, particularly in the context of Dementia with Lewy Bodies (DLB). They employ advanced brain imaging techniques to analyze the role of energy system failures in the progression of this neurodegenerative disease. Their research aims to uncover the mechanisms behind cognitive decline in DLB and identify potential therapeutic targets for neuroprotection.

Dr. Mervyn J. Monteiro's lab at the University of Maryland Baltimore focuses on understanding the mechanisms behind amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) caused by mutations in the UBQLN2 gene. Using advanced mouse models and cellular studies, the lab investigates how these mutations disrupt cellular processes that maintain protein balance and mitochondrial health, which are crucial for neuron function. The findings aim to unravel key pathways involved in neurodegeneration and could lead to potential therapeutic strategies for ALS and similar diseases.

Dr. Elizabeth Mormino's lab at Stanford University investigates how memory decline occurs in aging and early Alzheimer's disease. They focus on understanding how changes in the brain's structure and function, specifically in the hippocampus, relate to memory loss. By using cutting-edge imaging techniques and biofluid analysis, her team aims to develop models that predict individual memory decline, helping to identify early pathways of Alzheimer's before major symptoms develop.

Dr. John Morris's lab at Washington University focuses on understanding Alzheimer's disease by investigating early biomarkers in middle-aged individuals, especially those with a family history of the disease. The lab studies how changes in the brain can indicate the potential onset of Alzheimer's, even before symptoms appear. Through various projects, they explore factors that may influence the progression from preclinical conditions to symptomatic Alzheimer's while examining biological tests and lifestyle factors that may impact brain health.

Dr. John Compton Mosher's lab focuses on developing a new digital biomarker for the early detection of Alzheimer's disease. They aim to create a noninvasive, low-cost testing method using advanced EEG technology to identify key brain signals associated with Alzheimer's. This innovative approach could revolutionize how the disease is screened, making it easier to catch in its early stages before severe symptoms appear.

Dr. Jan R. Wessel's research focuses on understanding the effects of deep-brain stimulation (DBS) on motor control, specifically in patients with Parkinson's disease. His lab investigates the paradoxical effects of DBS on the ability to inhibit movements, exploring how different factors such as the location of the stimulation leads and brain connectivity influence motor function. This research aims to improve therapeutic approaches for treating Parkinson's disease and provides insights into fundamental brain mechanisms controlling movement.

Dr. Joshua E. Aman’s lab at the University of Minnesota focuses on understanding the brain mechanisms involved in movement disorders, particularly bradykinesia in Parkinson's disease. By studying neural activity in specific brain pathways, they aim to develop personalized deep brain stimulation therapies that enhance motor function and reduce symptoms. Their research utilizes advanced imaging techniques and real-time data collection during surgical procedures to unravel complex brain interactions that contribute to motor control.

Dr. Ulrich Mueller's laboratory at Johns Hopkins University focuses on understanding the function of hair cells in the inner ear, which are critical for hearing. The lab studies specific genes linked to hearing loss and how those genes affect the development and function of these hair cells. Researchers investigate the mechanisms of signal transmission in auditory circuits and the impact of genetic mutations on hearing capability.

Dr. Nancy L. Monson's lab at UT Southwestern focuses on understanding how multiple sclerosis (MS) affects minority populations, particularly African Americans and Hispanics, who experience more severe disease progression compared to Whites. The lab investigates the role of immune responses, especially the expansion of specific immune cells called plasmablasts, in worsening the disease. The goal is to uncover mechanisms behind these disparities and develop better diagnostic and treatment strategies for MS in these populations.

Dr. Susan A. Gauthier's lab focuses on understanding multiple sclerosis (MS), specifically how chronic inflammation affects the brain and cognitive function in patients. By using advanced imaging techniques, her team aims to identify biomarkers for treatment effectiveness and develop personalized therapies. Their research explores both structural and functional changes in the brain as MS progresses, ultimately seeking to improve patient care and outcomes.

Un Jung Kang's research lab focuses on understanding multiple system atrophy (MSA), a rare and fatal neurodegenerative disease. The lab uses advanced single nucleus RNA sequencing techniques to investigate how different brain cells are affected by MSA. By analyzing gene expression changes in postmortem brain tissue from MSA patients, the lab aims to uncover mechanisms leading to neuronal death and explore potential therapeutic targets.

Dr. Jeannette R. Mahoney's lab focuses on understanding how sensory and motor functions may indicate early signs of Alzheimer's disease. They study how the brain integrates information from different senses, which might serve as early markers for preclinical Alzheimer's. Through their research, they aim to improve our understanding of Alzheimer's pathology and develop interventions that could help older adults maintain their mobility and independence.

Dr. Towfique Raj's research lab focuses on understanding the role of immune cells, particularly myeloid cells, in Parkinson's Disease (PD). By analyzing genetic variants and their effects on these cells, the lab aims to bridge the gap between genetic associations and the biological mechanisms that lead to PD. Their work involves advanced techniques in transcriptomics and proteomics to uncover how these immune cells function differently in individuals with PD compared to healthy individuals, potentially leading to breakthroughs in treatment.

Dr. James J. Dowling's lab focuses on understanding a severe childhood muscle disease called X-linked myotubular myopathy (XLMTM), which is caused by mutations in the MTM1 gene. The research investigates the role of this gene in muscle development by exploring how MTM1 affects nuclear structures and gene expression related to muscle maturation. Through innovative mouse models and cutting-edge techniques, the lab aims to uncover the mechanics of this disease and contribute to potential therapy development.

Dr. Michael Nader's lab focuses on understanding how social factors and sex differences influence cocaine use and addiction through studies on monkeys. By exploring the interactions between behavior, environment, and biology, the lab aims to identify effective treatment strategies for cocaine use disorders. The research could help develop personalized medicine approaches to better tackle drug addiction based on individual needs.

Dr. Matthew Nassar's lab at Brown University investigates how the brain helps people adjust their behavior in response to changes in their environment. Specifically, the lab examines how arousal, mainly influenced by a system in the brain called locus coeruleus norepinephrine (LC/NE), affects behavioral flexibility. This research has important implications for understanding and treating psychiatric disorders where individuals struggle to adapt to new or stressful situations. By using advanced techniques like fMRI and computational modeling, the lab aims to uncover the underlying mechanisms that drive these behaviors in different individuals.